title: Helicobacter pylori eradication - an update on the latest therapies.
abstract: BACKGROUND
  The eradication of Helicobacter pylori (H. pylori) can be challenging in certain circumstances. There is no current first-line therapy that is curative in all patients.
  
  
  OBJECTIVE
  This article summaries the role of emerging novel therapies in the treatment of  H. pylori. Known as sequential therapy and salvage therapy, these new therapeutic strategies are thought to produce eradication rates superior to currently recommended first-line therapies. This article outlines the growing body of evidence supporting their efficacy.
  
  
  CONCLUSIONS
  Sequential therapy and salvage therapy have emerged recently as alternative regimens for the eradication of H. pylori. Although current guidelines continue to recommend established therapies for first-line management of H. pylori, general practitioners should be aware of these new strategies such that these options could be applied when traditional therapy fails.
authors.affiliation: is a medical student, Griffith University, Gold Coast, Queensland.
authors.forename: Julian
authors.initials: J
authors.lastname: Yaxley
authors.forename: Bhaskar
authors.initials: B
authors.lastname: Chakravarty
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D055118:Medication Adherence; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors